Brazil and India are some of the countries that produce a substantial amount of generic drugs and have been involved in a few cases regarding parallel import and seizure of generic medicines. Another issue that we have seen is Brazil and India joining the TRIPs Agreement and thus, in need of changing their IP regulatory frameworks. Indeed, we have noted the ongoing debate of the impact of these on access to medicines in developing countries.
For this reason, I announce with pleasure the publication of the book
Edward Elgar Publishing mentions that the book “analyzes national strategies to promote pharmaceutical innovation, while at the same time assuring widespread access to medicines through generic pharmaceutical production and generic pharmaceutical importation”. The book contains 12 Chapters written by authors from different countries- covering national experiences. Four of the Chapters cover Latin American jurisdictions and you do not need to guess to know that Brazil is there.
The book is on sale in the UK and sooner than later in the US. Thanks need to go to Dr Kenneth C. Shadlen, London School of Economics and Political Science, UK, one of the editors of the book for making the blog aware of this publication.